Inhibitors | Comment | Organism | Structure |
---|---|---|---|
NEM | - |
Homo sapiens |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
0.045 | - |
ancrod | enzyme form FTB | Homo sapiens | |
0.047 | - |
3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al | enzyme form FTB | Homo sapiens | |
0.1 | - |
3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al | enzyme form FTA | Homo sapiens | |
0.16 | - |
2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn | enzyme form FTB | Homo sapiens | |
0.167 | - |
asialo ancrod | enzyme form FTB | Homo sapiens | |
0.4 | - |
2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn | enzyme form FTA | Homo sapiens | |
0.63 | - |
fetuin triantennary asialoglycopeptide | enzyme form FTB | Homo sapiens | |
0.67 | - |
NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn | enzyme form FTB | Homo sapiens | |
0.77 | - |
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe | enzyme form FTB | Homo sapiens | |
1.43 | - |
fetuin triantennary glycopeptide | enzyme form FTB | Homo sapiens | |
1.52 | - |
Fucalpha(1,2)Galbeta(1,4)Glc | enzyme form FTB | Homo sapiens | |
2.5 | - |
NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn | enzyme form FTA | Homo sapiens | |
3.3 | - |
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe | enzyme form FTB | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Purification (Comment) | Organism |
---|---|
two molecular forms: FTA and FTB | Homo sapiens |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
lung cancer cell | - |
Homo sapiens | - |
Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|
0.061 | - |
- |
Homo sapiens |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
GDP-beta-L-fucose + fetuin triantennary asialoglycopeptide | - |
Homo sapiens | ? | - |
? | |
GDP-L-fucose + 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn | - |
Homo sapiens | GDP + 2-O-MeGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn | - |
? | |
GDP-L-fucose + 3-O-MeGalbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn | 16.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 17.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + 3-O-MeGalbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn | - |
? | |
GDP-L-fucose + 3-O-sulfoGalbeta(1,3)GlcNAcbeta(1,3)Galbeta-O-Al | 64.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 82.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + 3-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta-O-Al | - |
? | |
GDP-L-fucose + 3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al | 64.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 62.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + 3-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Al | - |
? | |
GDP-L-fucose + 3-O-sulfoGalbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn | 10.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 14.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + 3-O-sulfoGalbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn | - |
? | |
GDP-L-fucose + 6-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al | 3.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + 6-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Al | - |
? | |
GDP-L-fucose + ancrod | - |
Homo sapiens | GDP + ? | - |
? | |
GDP-L-fucose + asialo ancrod | - |
Homo sapiens | GDP + ? | - |
? | |
GDP-L-fucose + fetuin triantennary glycopeptide | - |
Homo sapiens | GDP + ? | - |
? | |
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)Glc | 34.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 38.7% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))Glc | - |
? | |
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAcbeta-O-Naph | 42.6 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 46.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Naph | - |
? | |
GDP-L-fucose + Galbeta(1,3)(6-O-sulfo)GlcNAcbeta(1,3)Galbeta-O-Al | 15.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 19.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + ? | - |
? | |
GDP-L-fucose + Galbeta(1,3)GlcNAc | 45.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 51% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc | - |
? | |
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta-O-Bn | 79.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 83.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn | - |
? | |
GDP-L-fucose + Galbeta(1,4)GlcNAc | 3.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc | - |
? | |
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(3-O-MeGalbeta(1,3))GalNAcalpha-O-Bn | 2.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(3-O-MeGalbeta(1,3))GalNAcalpha-O-Bn | - |
? | |
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(3-O-sulfoGalbeta(1,3))-GalNAcalpha-O-Bn | 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(3-O-sulfoGalbeta(1,3))-GalNAcalpha-O-Bn | - |
? | |
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn | 2.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn | - |
? | |
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta-O-Bn | 3.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 2.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta-O-Bn | - |
? | |
GDP-L-fucose + GalNAcbeta(1,3)(6-O-sulfo)GlcNAcbeta-O-Me | 6.2 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 8.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + ? | - |
? | |
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn | 55.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 64.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn | - |
? | |
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe | 24.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 12.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe | - |
? | |
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta-O-Bn | 6.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 7.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB | Homo sapiens | GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta-O-Bn | - |
? | |
additional information | high substrate affinity for clustered units of 3-sialyl Galbeta(1,3)GlcNAcbeta in asparagine linked carbohydrate as well as for mucin core 2 structure containing 3-sialyl Galbeta1,4GlcNAcbeta-unit, in addition of alpha(1,2)-L-fucosylating activity | Homo sapiens | ? | - |
? |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.25 | - |
NEM | enzyme form FTA and FTB | Homo sapiens |